Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia
-- Application marks the first protein-based COVID-19 vaccine submitted to regulatory authorities for provisional approval in Australia
-- In addition to today's submission to the Therapeutic Goods Administration, the company recently filed for authorization with MHRA, with additional filings in process
-- All modules required for Australian regulatory evaluation, including Quality/ CMC data, are now complete
